# US 2023/0145050 A1 · Sulphonyl urea derivatives as nlrp3 inflammasome modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0145050 A1
- Document ID: US20230145050A1
- Status: Published application
- Kind: A1
- Application number: 17/967,599
- Filed: 2022-10-17
- Published: 2023-05-11
- Earliest claimed: 2017-12-18
- Assignees: NodThera Limited
- Applicants: NodThera Limited
- Inventors: David HARRISON; Alan Paul WATT; Mark G. BOCK
- Web page: https://patentgrep.com/patent/US20230145050A1

## CPC

- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 231/38: Nitrogen atoms (nitro radicals C07D231/16)
- C07D 237/20: Nitrogen atoms (nitro radicals C07D237/12)
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 249/04: 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D 249/14: Nitrogen atoms
- C07D 261/14: Nitrogen atoms
- C07D 277/52: to sulfur atoms, e.g. sulfonamides
- C07D 285/135: Nitrogen atoms
- C07D 307/66: Nitrogen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D 471/08: Bridged systems
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

## Claims

### Claim 1

(canceled)

### Claim 2

A compound of Formula (Iac-1):
or a prodrug, solvate, or pharmaceutically acceptable salt thereof, wherein:
R2 is —(CX2X2)n—R2S, wherein n is 0, 1, or 2, and each X2 is independently H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl is optionally substituted with one or more halo, —CN, —OH, —O(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, or oxo;
R2S is 4- to 8-membered heterocycloalkyl optionally substituted with one or more C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, halo, —CN, —OH, —O(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, or oxo; and
each R3S is independently C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, halo, —CN, or C3-C8 heterocycloalkyl, wherein the C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, or C3-C8 heterocycloalkyl is optionally substituted with —O(C1-C6 alkyl), —N(C1-C6 alkyl)2, halo, or —CN.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R2 is —R2S.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R2 is —(CH2)—R2S.

### Claim 5 (depends on 3)

The compound of claim 3, wherein R2S is 4- to 8-membered heterocycloalkyl optionally substituted with one or more C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, halo, —CN, —OH, —O(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, or oxo.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R2S is

### Claim 7 (depends on 1)

The compound of claim 1, wherein each R3S is independently C1-C6 alkyl optionally substituted with —O(C1-C6 alkyl), —N(C1-C6 alkyl)2, halo, or —CN.

### Claim 8 (depends on 7)

The compound of claim 7, wherein at least one R3S is methyl, ethyl, or isopropyl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound is of Formula (Iabc-1):
or a prodrug, solvate, or pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The compound of claim 1, wherein the compound is of Formula (Iabc-1a):
or a prodrug, solvate, or pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The compound of claim 1, wherein the compound is selected from:
or a prodrug or pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The compound of claim 1, wherein the compound is:
or a prodrug or pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is:
or a prodrug or pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is:
or a prodrug or pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound is:
or a prodrug or pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The compound of claim 1, wherein the compound is:
or a prodrug or pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 12)

A pharmaceutical composition comprising the compound of claim 12 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

### Claim 18 (depends on 13)

A pharmaceutical composition comprising the compound of claim 13 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

### Claim 19 (depends on 14)

A pharmaceutical composition comprising the compound of claim 14 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

### Claim 20 (depends on 15)

A pharmaceutical composition comprising the compound of claim 15 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

### Claim 21 (depends on 16)

A pharmaceutical composition comprising the compound of claim 16 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
